280 related articles for article (PubMed ID: 31630284)
1. Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer.
Metcalf S; Dougherty S; Kruer T; Hasan N; Biyik-Sit R; Reynolds L; Clem BF
Clin Exp Metastasis; 2020 Feb; 37(1):187-197. PubMed ID: 31630284
[TBL] [Abstract][Full Text] [Related]
2. Serine Biosynthesis Is a Metabolic Vulnerability in IDH2-Driven Breast Cancer Progression.
Barnabas GD; Lee JS; Shami T; Harel M; Beck L; Selitrennik M; Jerby-Arnon L; Erez N; Ruppin E; Geiger T
Cancer Res; 2021 Mar; 81(6):1443-1456. PubMed ID: 33500247
[TBL] [Abstract][Full Text] [Related]
3. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
[TBL] [Abstract][Full Text] [Related]
4. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
5. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis.
Pollari S; Käkönen SM; Edgren H; Wolf M; Kohonen P; Sara H; Guise T; Nees M; Kallioniemi O
Breast Cancer Res Treat; 2011 Jan; 125(2):421-30. PubMed ID: 20352489
[TBL] [Abstract][Full Text] [Related]
6. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.
Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL
Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical significance of flap endonuclease‑1 in triple‑negative breast cancer: Support of metastasis and a poor prognosis.
Xu L; Qu JL; Song N; Zhang LY; Zeng X; Che XF; Hou KZ; Shi S; Feng ZY; Qu XJ; Liu YP; Teng YE
Oncol Rep; 2020 Dec; 44(6):2443-2454. PubMed ID: 33125141
[TBL] [Abstract][Full Text] [Related]
8. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.
Gagliardi M; Pitner MK; Park J; Xie X; Saso H; Larson RA; Sammons RM; Chen H; Wei C; Masuda H; Chauhan G; Kondo K; Tripathy D; Ueno NT; Dalby KN; Debeb BG; Bartholomeusz C
Sci Rep; 2020 May; 10(1):8537. PubMed ID: 32444778
[TBL] [Abstract][Full Text] [Related]
9. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
Das SG; Romagnoli M; Mineva ND; Barillé-Nion S; Jézéquel P; Campone M; Sonenshein GE
Breast Cancer Res; 2016 Apr; 18(1):40. PubMed ID: 27039296
[TBL] [Abstract][Full Text] [Related]
10. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
[TBL] [Abstract][Full Text] [Related]
11. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
[TBL] [Abstract][Full Text] [Related]
12. Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
Zhang X; Bai W
Cancer Chemother Pharmacol; 2016 Sep; 78(3):655-9. PubMed ID: 27473325
[TBL] [Abstract][Full Text] [Related]
13. Rhophilin-associated tail protein 1 promotes migration and metastasis in triple negative breast cancer via activation of RhoA.
Liu Q; Huang X; Li Q; He L; Li S; Chen X; Ouyang Y; Wang X; Lin C
FASEB J; 2020 Aug; 34(8):9959-9971. PubMed ID: 32427399
[TBL] [Abstract][Full Text] [Related]
14. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
Humphries B; Wang Z; Oom AL; Fisher T; Tan D; Cui Y; Jiang Y; Yang C
Carcinogenesis; 2014 Oct; 35(10):2254-63. PubMed ID: 24925028
[TBL] [Abstract][Full Text] [Related]
16. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
17. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of signaling protein ERN1 increases the sensitivity of serine synthesis gene expressions to glucose and glutamine deprivations in U87MG glioblastoma cells.
Minchenko OH; Sliusar MY; Khita OO; Minchenko DO; Viletska YM; Halkin OV; Levadna LO; Cherednychenko AA; Khikhlo YP
Endocr Regul; 2024 Jan; 58(1):91-100. PubMed ID: 38656254
[No Abstract] [Full Text] [Related]
19. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
[TBL] [Abstract][Full Text] [Related]
20. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
